← Back to patent-cliff list
CAS 14714-18-2
ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate
Codes: GAND-014
Application context (from source-drug indications)
Haematological malignancyGandotinibMyelofibrosisGandotinibMyeloproliferative neoplasmGandotinibEssential thrombocythaemiaGandotinibPolycythaemia veraGandotinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Gandotinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
6-chloropyridazin-3-amine→4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine→ethyl 2-chloro-3-oxobutanoate→ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate→ethyl 6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazine-3-carboxylate→4-((6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine→4-((6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.